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C3 glomerulopathies (C3G) are a group of severe renal diseases with distinct patterns of glomerular inflam-
mation and C3 deposition caused by complement dysregulation. Here we report the identification of a familial 
C3G-associated genomic mutation in the gene complement factor H–related 1 (CFHR1), which encodes FHR1. 
The mutation resulted in the duplication of the N-terminal short consensus repeats (SCRs) that are conserved 
in FHR2 and FHR5. We determined that native FHR1, FHR2, and FHR5 circulate in plasma as homo- and 
hetero-oligomeric complexes, the formation of which is likely mediated by the conserved N-terminal domain. 
In mutant FHR1, duplication of the N-terminal domain resulted in the formation of unusually large multi-
meric FHR complexes that exhibited increased avidity for the FHR1 ligands C3b, iC3b, and C3dg and enhanced 
competition with complement factor H (FH) in surface plasmon resonance (SPR) studies and hemolytic assays. 
These data revealed that FHR1, FHR2, and FHR5 organize a combinatorial repertoire of oligomeric complexes 
and demonstrated that changes in FHR oligomerization influence the regulation of complement activation. In 
summary, our identification and characterization of a unique CFHR1 mutation provides insights into the biol-
ogy of the FHRs and contributes to our understanding of the pathogenic mechanisms underlying C3G.
Introduction
The family of factor H–related proteins (FHRs) includes 5 plasma 
proteins, FHR1–FHR5, with concentrations ranging 5–50 μg/ml, 
that are structurally and functionally related to factor H (FH), the 
main regulator of the alternative pathway of complement activation 
(1). The genes encoding these FHRs, CFHR1–CFHR5, are located 
downstream and are closely linked to the FH gene (CFH), from which 
they likely originated by tandem duplication events (ref. 2 and Sup-
plemental Figure 1; supplemental material available online with this 
article; doi:10.1172/JCI68280DS1). Although it is generally accepted 
that the FHRs influence complement activation and regulation via 
their interaction with C3b, iC3b, and C3dg fragments and carbohy-
drates on surfaces, how this occurs remains controversial.
All FHRs retain the C-terminal region of FH (Supplemental 
Figure 1), with different degrees of sequence conservation, which 
explains their ability to interact with C3b, iC3b, C3dg, and carbo-
hydrates (1, 3, 4) and justifies the concept that FHRs compete with 
FH for binding to specific surfaces, enhancing alternative pathway 
(AP) activation. Weak cofactor and/or decay-accelerating activities 
have also been reported for some of the FHRs (3–7), suggestive of 
intrinsic complement regulatory activity.
The CFH-CFHR1-CFHR5 gene region shows significant genetic 
variability that has been repeatedly associated with pathology 
(reviewed in ref. 8). In addition to conventional polymorphisms 
due to sequence variations, the presence within this region of large 
genomic duplications (ranging 1.2–38 kb in size) makes the region 
highly prone to genomic rearrangements through gene conversion 
and nonhomologous recombination events (2). Many of these 
CFH-CFHR1-CFHR5 gene rearrangements have been associated 
with a number of chronic and infectious diseases. Interestingly, 
deletion of the CFHR1 and CFHR3 genes (ΔCFHR3-CFHR1), a common 
polymorphism in humans, is associated with lower risk for age-
related macular degeneration (AMD) (9) and IgA nephropathy 
(10), whereas generation of mutant FHRs by gene fusion or inter-
nal duplication events has been associated with increased risk for 
kidney diseases, like atypical hemolytic uremic syndrome (aHUS) 
and C3 glomerulopathy (C3G) (11–13).
C3G is a heterogeneous group of kidney pathologies associated 
with complement dysregulation and classified histologically by C3 
predominant glomerulonephritis. In C3G of the dense deposit dis-
ease type (DDD), the dense material appears within the glomerular 
basement membrane (GBM), whereas in C3 glomerulonephritis 
(C3-GN), it is predominantly mesangial and/or subendothelial in 
location (14). Phenotypes that are intermediate between DDD and 
C3-GN also occur.
We report here the identification of a mutant FHR1 protein 
associated with C3G that highly resembled the mutant FHR5 
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protein, with an internal duplication of short consensus repeat 1 
(SCR1) and SCR2 that has been associated with familial C3-GN 
among individuals with Cypriot ancestry (15). It also resembled 
the hybrid FHR2::FHR5 protein reported by Chen et al. in a DDD 
pedigree, in which SCR1 and SCR2 of FHR2 are fused to the full-
length FHR5 protein (11). A striking common characteristic of 
these 3 mutant FHRs associated with C3G is the duplication of 
the 2 N-terminal SCRs that are virtually identical in the FHR1, 
FHR2, and FHR5 proteins (Supplemental Figure 1). The inheri-
tance pattern of these mutations as a dominant trait underlies the 
functional relevance of the N-terminal region of these FHRs and 
suggests a gain-of-function outcome.
Based on these data, we hypothesized that characterization of 
the structural organization of the human proteins FHR1, FHR2, 
and FHR5 in plasma would be critical for understanding the func-
tional consequences of the mutant FHR1 protein. Our data dem-
onstrated that FHR1, FHR2, and FHR5 circulated in plasma as 
homo- and hetero-oligomeric complexes and suggested that the 
N-terminal SCR1 and SCR2 are involved in the oligomerization. 
The structural organization of FHR1, FHR2, and FHR5 in plasma 
helps to understand how these proteins influence complement 
activation and regulation. Crucially, multimerization as a con-
sequence of duplication of the oligomerization domains in the 
mutant FHR1 protein increased binding to C3b, iC3b, and C3dg 
and resulted in enhanced competition with FH. Taken together, 
these structural and functional data explain how mutant FHR1 
causes complement dysregulation and reveal a novel pathogenic 
mechanism of C3G.
Results
A familial case of C3G associated with an internal duplication of CFHR1. We 
present the case of a 12-year-old boy (GN29), his mother (GN29M), 
and his maternal grandfather (GN29GF); see Methods for detailed 
clinical presentation and development of disease. Biopsies in all 
showed C3G (Figure 1). Ultrastructural changes were heterogeneous: 
in GN29, deposits were present within the GBM and mesangium; 
in GN29M, accumulation of electron-dense material was found in 
subendothelial and subepithelial GBM locations (Figure 1).
We were able to collect samples from the 2 affected members 
alive in the pedigree, GN29 and GN29M, and from 2 healthy rela-
tives, GN29B and GN29U (Figure 2A). Complement analysis in the 
proband and his mother illustrated persistent decreased levels of 
C3 compared with their healthy relatives (Figure 2B), which sug-
gests significant activation of complement. Notably, C3 levels in 
these patients, although decreased, were significantly higher than 
those usually found in DDD patients. Assays to identify C3Nef or 
anti-FH autoantibodies were negative. Levels of membrane cofac-
tor protein (MCP; also known as CD46) on the surface of periph-
eral blood lymphocytes were normal in both patients. Levels of 
factor I (FI), factor B (FB), and FH were also normal.
Routine Western blot analysis to characterize anomalies in 
the FHRs, performed as previously described (16), identified an 
anomalous FHR band of approximately 70 kDa in the proband 
and his mother that was absent in their healthy relatives (Fig-
ure 2C). Proteomic analysis of material from this band revealed 
that it exclusively contained sequences corresponding to FHR1 
(Supplemental Figure 2). Multiplex ligation-dependent probe 
Figure 1
Histology, immunofluorescence, and EM findings. Kidney biopsies from probate GN29 (A–G) and his mother, GN29M (H–O), showed remarkably 
similar light, immunofluorescence, and ultrastructural findings. The characteristic histological lesion consisted of mesangial hypercellularity with 
thickened, eosinophil-rich segments of GBM (A and H). The affected glomerular segments were PAS positive and reacted to trichrome and Jones 
methenamine-silver stain (B, C, and I–K). The main immunofluorescence findings were prominent and diffuse C3 deposits, which were granular in 
some glomerular areas (D and L). IgG was absent from these deposits (F and M), although local deposits of IgM were observed in GN29 (E). Both 
biopsies showed similar ultrastructural alterations (G, N, and O) consisting of the presence of ribbon-like, osmiophilic deposits in the GBM (arrows); 
these electron-dense deposits were also evident in the mesangial matrix (asterisks). Original magnification, ×400 (A–C, H, and I); ×200 (D–F); ×1,600 
(G); ×600 (J and K); ×100 (L and M); ×2,950 (N); ×8,900 (O).
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amplification (MLPA) analysis identified 2 rearrangements in the 
CFHR1-CFHR5 region segregating in this pedigree, the polymor-
phic deletion of the CFHR3 and CFHR1 genes (ΔCFHR3-CFHR1) and 
a partial duplication of the CFHR1 gene, which was only carried 
by the affected individuals (Supplemental Figure 3A) and likely 
explains the anomalous FHR1 band found by Western blot in 
these individuals. To further characterize this CFHR1 genomic 
rearrangement, genomic DNA from the proband was analyzed 
in a custom-made high-density comparative genomic hybridiza-
tion (CGH) 15k array (see Methods), which was designed to iden-
tify copy number variations within the regulators of complement 
activation (RCA) gene cluster. These analyses revealed an internal 
duplication of exons 2–5 in CFHR1 that predicted a mutant FHR1 
protein (Figure 2D), consistent with the anomalous FHR1 band 
detected in the proband and his affected mother. Long PCR ampli-
fication analyses using primers to exons 5 and 2 of CFHR1 resulted 
in the generation of DNA fragments that confirmed the fusion of 
intron 5 to intron 1 (Supplemental Figure 3B). As a whole, these 
data demonstrate that in pedigree GN29, the disease segregates 
with an anomalous mutant FHR1 protein resulting from an inter-
nal duplication of the CFHR1 gene. This protein had 9 SCRs, with 
the first 4 duplicated in tandem (Figure 2E). Thus, the mutant 
FHR1 protein was expressed at concentrations similar to those of 
the native FHR1 protein and could be easily detected in the plasma 
of the mutation carriers.
The mutant FHR1 protein resembles the mutant FHR5 
originally described by Gale et al. in Cypriots (14), and the 
FHR2::FHR5 hybrid protein described by Chen et al. (11), in 
the sense that each of these 3 mutant proteins is characterized 
by the duplication of SCR1 and SCR2. In all cases, these aber-
rant proteins were associated with C3G, either DDD or C3-GN. 
Interestingly, the disease showed full penetrance in the carriers 
of these 3 mutations. It also segregated as a dominant trait, 
which suggests that, in contrast to the protective effect of the 
ΔCFHR3-CFHR1 allele, duplication of the N-terminal region of these 
FHRs results in a gain of function.
Native FHR1 interacts with FHR2 and FHR5, but not with FH, FHR3, 
or FHR4A/B. To understand the functionality of the N-terminal 
SCR1 and SCR2 domains of FHR1 and to determine the conse-
quences of the duplication of this region in the FHR1 protein, we 
purified native FHR1 from FH-depleted human EDTA plasma 
using, as a first step, heparin chromatography with a 50- to 350-
Figure 2
Internal duplication of CFHR1 is associated with C3G in pedigree GN29. (A) The GN29 pedigree. Affected individuals are indicated with solid 
symbols; carriers of the mutant FHR1 and of ΔCFHR3-CFHR1 are indicated with solid circles and triangles, respectively. (B) Levels of C3 in affected 
and healthy individuals in the GN29 pedigree. (C) Western blot of whole human plasma identifying FH, FHL1, and FHR1 with an in-house rabbit 
polyclonal anti-FH. An anomalous band of approximately 70 kDa was identified in the proband and his mother. Proteomic analysis of material 
from this band demonstrated that this band was the product of a mutant CFHR1 gene (Supplemental Figure 2). (D) High-resolution CGH array 
of the CFH-CFHR1 locus, illustrating an internal duplication of CFHR1 in the genomic DNA from GN29, encompassing exons 2–5. (E) Putative 
structure of a 9-SCR protein encoded by the mutant CFHR1. Red denotes duplicated SCRs.
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mM NaCl gradient. Although FHR1 was fully retained on the hep-
arin column, this chromatographic fractionation did not result in 
a single elution peak containing FHR1; instead, FHR1 eluted in 4 
distinct peaks at different NaCl concentrations. Immunodetection 
of FHR2 and FHR5 in the eluted fractions using the mouse mAb 
MBC125 (which recognizes an epitope common to FHR1, FHR2, 
and FHR5) showed that these 2 proteins, which were also fully 
retained in the heparin column, coeluted with FHR1 in the NaCl 
gradient (Figure 3). FHR2 coeluted with FHR1 in 2 distinct peaks: 
in peak 1, FHR1 and FHR2 appeared equimolar (FHR1-FHR2), 
whereas in peak 2, FHR1 was approximately 3 times more abun-
dant than FHR2 (FHR13-FHR2). In peak 3, FHR1 eluted alone, 
and in peak 4, both FHR1 and FHR5 were present (FHR1-FHR5) 
(Figure 3). Identical results were obtained with FH-depleted plas-
ma from individuals with each of the 3 CFHR1*A/B genotypes 
(Figure 3 and ref. 17), which indicates that the peculiar FHR1 
Figure 3
Heparin chromatography of FHR1, FHR2, and FHR5 proteins. Elution profiles of FHR1, FHR2, and FHR5 from individuals of the 3 CFHR1*A/B 
genotypes illustrated that FHR1 eluted in 4 distinct peaks at different NaCl concentrations. Top: Representative case of how plasma proteins 
retained in the heparin column were eluted with the NaCl gradient. Bottom: Western blots used the MBC125 mAb to determine the elution posi-
tion of the different FHRs. Peaks 1–4 are indicated. FHR1 coeluted with FHR2 in the first 2 peaks: in peak 1, FHR1 and FHR2 showed equimolar 
quantities (FHR1-FHR2); in peak 2, FHR1 was approximately 3 times more abundant than FHR2 (FHR13-FHR2). In peak 3, FHR1 eluted alone, 
and in peak 4, FHR1 and FHR5 coeluted at approximately equimolar quantities (FHR1-FHR5). FHRs were identified simultaneously by Western blot 
using MBC125 mAb, which recognizes an epitope common to the 3 FHRs. Protein bands corresponding to FHR1, FHR2, and FHR5 are indicated 
at right. Also shown is Western blot of the elution profile corresponding to an individual homozygote for the ΔCFHR3-CFHR1 allele, illustrating that FHR2 
was not retained in the column in the absence of FHR1. Samples from the elution profiles were run in 3 separate gels. O, original; NR, nonretained.
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elution pattern was unrelated to the CFHR1 common polymor-
phism. Since no evidence of FHR1 posttranslational modifica-
tions was obtained to justify this complex FHR1 elution pattern, 
we concluded that it was a consequence of interaction of FHR1 
with other FHRs. Moreover, because the analysis of FH-depleted 
plasma from individuals lacking FHR1 demonstrated that in the 
absence of FHR1, FHR2 was not retained in the heparin column 
(Figure 3), we postulated that FHR1 interacts with FHR2 and 
FHR5. Using this method, we could not see any evidence of an 
interaction between FHR2 and FHR5: we could not detect retained 
FHR2 when FHR1 was absent, and we did not observe coelution of 
FHR2 with FHR5 when FHR1 was present.
To determine whether FHR1 also interacts with FH, FHR3, and 
FHR4A/B, a sample of EDTA plasma from a CFHR1*A/B hetero-
zygote was passed through a MBC125 affinity column, and the 
presence of FH and all FHRs was analyzed in the flow-through 
and retained fractions by Western blot using a panel of specific 
Abs. Since FH, FHR3, and FHR4A/B proteins were not retained, we 
concluded that they do not interact with FHR1, FHR2, and FHR5, 
which were retained on the column (Supplemental Figure 4).
These experiments also showed that, when eluted from the 
MBC125 column at pH 2.5 and renatured in PBS, FHR1, FHR2, 
and FHR5 demonstrated elution profiles from heparin columns 
identical to those obtained using FH-depleted plasma (Supple-
mental Figure 5). These data suggest either that the interactions 
between FHR1 and FHR2 (or FHR5) are very strong and are main-
tained through acid elution, or that formation of the different 
FHR complexes is a reversible process. In practical terms, this 
observation facilitated the development of a simple 2-step proto-
col for the purification of the different FHR1 complexes: affinity 
chromatographic purification from whole EDTA plasma using 
MBC125 mAb, and subsequent fractionation of the FHR1 com-
plexes by heparin chromatography.
FHR1 assembles into homo- and hetero-oligomeric complexes. Puri-
fied FHRs corresponding to the heparin chromatography elution 
peaks 1–4 (Figure 3), as well as FHR2 and FHR5 purified from the 
plasma of FHR1-deficient individuals, were analyzed by gel filtra-
tion using a Superdex 200 PC 3.2/30 column previously calibrated 
using 3 SCR-containing proteins of different sizes: FH (20 SCRs), 
C4bpαΔCT (8 SCRs), and soluble DAF (sDAF; 4 SCRs). 350 mM 
NaCl was used in these experiments to avoid interaction of the 
FHRs with the carbohydrate components in the column matrix. 
Interestingly, the different purified FHRs eluted as a single peak 
with an apparent size that was consistent with the size of a FHR 
Figure 4
FHR1, FHR2, and FHR5 assemble into homo- and hetero-oligomers. (A) Purified FHRs corresponding to the 4 FHR1-containing peaks from hepa-
rin chromatography, and FHR2 and FHR5 proteins purified from a FHR1-deficient individual, were analyzed in 4%–16% polyacrylamide native gels. 
sDAF (4 SCRs) and FH (20 SCRs) were used as molecular weight markers. Gels were silver stained. Protein complexes were obtained for each 
sample (bottom). (B) FHR composition of the numbered protein complexes in A was analyzed by SDS-PAGE. Comparison of the relative mobility of 
the bands obtained for each sample, together with the Western blot analysis, demonstrated the presence of different homo- and hetero-oligomeric 
complexes. For example, lanes 1, 4, and 5 were interpreted as FHR1, FHR5, and FHR2 homodimers, respectively. A faint and diffuse band (lane 
3) running below the band of the FHR1 dimer could correspond to a FHR5 monomer. Lane 6 did not contain FHR2 (likely a protein contamination). 
Therefore, there was only 1 protein complex in plasma containing FHR2 (likely a dimer). Lane 7 was a FHR1-FHR2 heterodimer: it contained both 
FHR1 and FHR2 and presented mobility intermediate between the FHR2 and FHR1 homodimers. Lanes 12 and 13 corresponded to different 
FHR1-FHR5 hetero-oligomers. Lanes were run on the same gel but were noncontiguous (black lines). (C) Putative structure of these complexes, 
based on structural data demonstrating that the first 2 N-terminal SCRs (orange) of these proteins formed dimers in a head-to-tail orientation (13). 
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Figure 5
Mutant FHR1 protein shows an abnormal heparin chromatography 
elution profile and assembles into high–molecular weight multim-
ers. (A) Elution profiles of the FHR1, FHR2, and FHR5 proteins 
from GN29M illustrated that the mutant FHR1 coeluted with FHR2 
in a major peak extending through most of the NaCl gradient and a 
minor peak at low NaCl concentration. Heparin fractions were char-
acterized by Western blot using MBC125. Samples from the elution 
profiles were run in 3 separate gels. (B) EDTA plasma from GN29M 
was passed through the MBC125 affinity column. The retained 
FHRs were eluted in 100 mM glycine, pH 2.5; dialyzed against PBS; 
and analyzed by size-exclusion Superdex 200 PC 3.2/30 chroma-
tography in 20 mM Tris-HCl (pH 7.5) and 350 mM NaCl (GN29M 
FHR1-FHR2). Purified proteins corresponding to the FHRs hepa-
rin chromatography elution peak 1 from a normal individual (Native 
FHR1-FHR2; corresponding to FHR1-FHR2 dimers) is also shown 
for size comparison. Also included is a preparation enriched of the 
high–molecular size species of the mutant FHR1 protein (Enriched 
Mut. FHR1). Proteins in the gel filtration fractions were characterized 
by Western blot and are shown below.
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dimer (Supplemental Figure 6), suggestive of the formation of 
homo- and heterodimers. The exception was FHRs in peak 4 (Fig-
ure 3), which eluted as 2 overlapping peaks. Evidence of FHR1-
FHR2 heterodimers was also obtained in immunoprecipitation 
experiments using mAb MBI-18, which specifically recognizes 
FHR2 (Supplemental Figure 7).
Purified proteins corresponding to the FHR heparin chromatog-
raphy elution peaks 1–4 were also analyzed in 4%–16% blue native–
PAGE (BN-PAGE), which provided formal proof of the existence of 
homo- and hetero-oligomers of the FHRs (Figure 4). FH and sDAF 
were included in these native gels as molecular weight markers, 
and the FHRs were visualized by silver staining and Western blot 
analysis (Figure 4A). Bands from the native gels corresponding to 
the different complexes were excised and further analyzed in 12% 
SDS-PAGE gels (Figure 4B). As a whole, these experiments were 
consistent with the existence of homo- and heterodimers of the 
different FHRs. Notably, in samples containing FHR1, they also 
identified higher-order oligomers, which we interpreted as tetra-
mers. For example, when purified FHRs included in peak 1 (frac-
tions A11 to B11; Supplemental Figure 5) were run in the native 
gels, 2 FHR complexes were obtained (Figure 4A), both of which 
contained FHR1 and FHR2 (Figure 4B, lanes 7 and 8). Interest-
ingly, the apparent sizes of the FHR oligomers containing FHR1 
and FHR2 were intermediate between those obtained from peaks 
containing only FHR1 or only FHR2, consistent with the size of 
the FHR1-FHR2 hetero-oligomers (Figure 4).
A tetrameric structure could explain the differences between 
peak 1 and peak 2 in the FHR heparin chromatography elution 
profiles (Figure 3). In fact, our native gels showed that peak 2 
contained both FHR1-FHR1 homodimers and FHR1-FHR2 het-
erodimers, which suggests that the FHRs within this peak assem-
ble into a tetramer formed by a FHR1-FHR1 homodimer and a 
FHR1-FHR2 heterodimer. In contrast, peak 1 only contained 
FHR1-FHR2 heterodimers, which suggests that it corresponds to 
a tetramer resulting from the interaction of 2 FHR1-FHR2 dimers. 
In agreement with this interpretation, when the purified proteins 
in peak 2 were denatured in 1M NaCl, dialyzed, and rechromato-
graphed in the heparin column, they again displayed peaks 1–3 
(Supplemental Figure 8).
Because we found only interactions among FHR1, FHR2, and 
FHR5, and these FHRs have almost identical N-terminal regions 
distinct from other FHRs, this region is the most likely candidate 
to mediate FHR oligomerization. It is unclear why FHR2 and 
FHR5 only formed homo-oligomers in the absence of FHR1.
The FHR1 mutant protein associated with C3G in the GN29 pedigree 
assembles into unusually large multimeric complexes. Consistent with 
the idea that the N-terminal region of FHR1 mediates homo- and 
hetero-oligomerization, analysis of the FHRs eluted from hepa-
rin chromatography from the FH-depleted plasma of GN29M 
showed an abnormal profile, with the mutant FHR1 coeluting 
with FHR2 through most of the NaCl gradient (Figure 5A). More-
over, gel filtration chromatographic analysis of the FHRs affin-
ity purified from the EDTA plasma of GN29M using MBC125 
revealed 2 major peaks containing the mutant FHR1 protein, one 
of them with a size considerably exceeding that of the normal 
FHRs analyzed under the same conditions (Figure 5B). We argued 
that these apparently large size structures were suitable for struc-
tural analysis by EM and set up experiments with purified native 
and mutant FHR1 complexes. Despite intensive effort, native 
FHR complexes could only be detected at high concentrations as 
an intersection of thin filaments corresponding to nearby mol-
ecules that were very close together. Unfortunately, these native 
FHR complexes were not visible upon dilution to the concentra-
tion required to separate individual molecules (data not shown). 
Similar behavior was observed for FH, which we interpreted as a 
limitation of the EM method. Thin filaments like those formed 
by FH and FHR1 were at the size limit for observation using EM; 
thus, they were only detected when several molecules were very 
close together or part of a larger complex. In contrast, we were 
able to visualize protein complexes in a preparation enriched for 
the large-size mutant FHR1 complexes (Figure 6). Importantly, 
these structures were detected at concentrations when individual 
molecules were separate, which suggests that FHR1 mutant com-
plexes are larger than native FHR1 proteins. Mutant FHR1 com-
plexes appeared as multimeric, bundle-like structures, each con-
taining several intersecting thin filaments. Interestingly, despite 
mutant FHR1 complexes displaying heterogeneous shapes with 
multiple arms in different orientations, their sizes were rather 
Figure 6
EM analyses of the mutant FHR1 high–molecular 
weight forms. (A) Typical field for a diluted sample 
of a negative-staining EM analysis of the purified 
mutant FHR1 enriched in high–molecular weight 
oligomers. Isolated complexes were detected as 
filaments of white density on the background of the 
micrograph. Scale bar: 50 nm. (B) Gallery of select-
ed images for single complexes, illustrating that 
each was composed of at least 2 elongated and 
flexible chains, presumably mutant FHR1 mono-
mers. The length of individual chains was mea-
sured (about 30 nm) and found to be in agreement 
with the estimated length of an elongated mutant 
FHR1 molecule composed of 9 SCR domains in 
tandem (approximately 3 nm per SCR domain). 
Scale bar: 25 nm.
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homogeneous, which indicates that the dimensions of the com-
plexes found were within a discrete range, and very large aggre-
gates were not detected. As a whole, the EM data support that 
mutant FHR1 is assembled into a larger multimeric complex.
GN29 mutant FHR1 shows increased interaction with surface-bound 
C3b, iC3b, and C3dg. To explore the functional consequences of 
the effect of multimerization on the mutant FHR1, we performed 
surface plasmon resonance (Biacore) experiments. Because we 
could not demonstrate complement inhibitory capabilities for 
FHR1 in preliminary analyses (Supplemental Figures 9–11), we 
therefore focused on the interaction of FHR1 with surface-bound 
C3 fragments. Our results showed that when C3b was immobi-
lized on a CM5 Biacore chip through the thioester group, mutant 
FHR1 bound more efficiently to C3b than the native FHR1 pro-
tein. The results illustrated fast binding and dissociation kinet-
ics for the native FHR1 protein, whereas binding of the mutant 
FHR1 showed much slower dissociation (Figure 7A). As expect-
ed, these results support the hypothesis that multimerization 
of FHR1 in the mutant protein increases avidity for its ligands, 
leading to much enhanced binding to C3b compared with native 
FHR1. Similar results were obtained with iC3b and C3dg. Bind-
ing of native and mutant FHR1 was comparable to that of FH on 
the same surfaces: FH bound well to the C3b surface, illustrat-
ing marked avidity effects as would be expected on the “clustered 
C3b” surface. Conversion to iC3b almost eliminated binding of 
FH, whereas native and mutant FHR1 bound almost as well to 
iC3b as to C3b (Figure 7B).
GN29 mutant FHR1 shows enhanced competition with FH. As a con-
sequence of binding more efficiently to its ligands, the mutant 
FHR1 protein may compete better with FH. To investigate this 
Figure 7
Mutant FHR1 shows increased binding to surface-bound C3b, iC3b, and C3dg. (A) SPR analysis of native (black lines) and mutant (gray lines) 
FHR1 binding to C3b, iC3b, and C3dg. C3b (150 RU) was amine-coupled to a CM5 Biacore chip and used as a nidus for convertase formation. 
Further C3b (1,240 RU) was deposited on the chip surface by flowing FB and FD to form C3bBb, followed by C3 as convertase substrate. The 
surface C3b was converted to iC3b by incubating with FH and FI until the surface no longer supported convertase formation. Conversion to C3dg 
was achieved by incubating the iC3b surface with soluble CR1 and FI until no further C3c was released. 1:2 serial dilutions from 28 μg/ml native 
and mutant FHR1 were flowed across the surface for 3 minutes, then allowed to dissociate for 3 minutes prior to regenerating the surface. Avid-
ity effects affecting dissociation of mutant FHR1 are clear. (B) Comparative binding of native and mutant FHR1 and FH to C3b and iC3b. Serial 
dilutions of native FHR1 (WT; 28 μg/ml), mutant FHR1 (Mut; 28 μg/ml), and FH (bottom; 26 μg/ml) were flowed across the C3b surface (gray 
lines) as described in A. The surface C3b was converted to iC3b by incubating with FH and FI until the surface no longer supported convertase 
formation. Native and mutant FHR1 as well as FH were flowed across iC3b (black lines) at identical concentrations as in A. Binding of native or 
mutant FHR1 was little affected by conversion of C3b to iC3b, whereas binding of FH was almost eliminated.
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possibility, we tested native and mutant FHR1 in a variation of 
the FH-dependent hemolytic assay previously developed in our 
laboratory (12). In this modified assay, a human serum sample 
was incubated with guinea pig erythrocytes (instead of the sheep 
erythrocytes used in the original assay) in the presence of 5 mM 
MgCl2 and 8 mM EGTA. Guinea pig erythrocytes were efficiently 
lysed in this assay, but lysis could be prevented by the addition of 
extra FH (Figure 8, inset). Importantly, FHR1 competed with FH 
in a dose-dependent manner, influencing control of the AP on the 
surface of the guinea pig erythrocytes. As shown in Figure 8, the 
mutant FHR1 protein competed with FH more efficiently than 
did native FHR1. These data indicate that multimerization as a 
consequence of duplication of the N-terminal region enhances 
competition with FH for certain surfaces, resulting in increased 
activation of the complement AP.
Discussion
We report here the identification of a mutant FHR1 protein (car-
rying a duplication of the N-terminal region conserved in FHR1, 
FHR2, and FHR5) in a Spanish pedigree with multiple C3G-affect-
ed individuals. This finding made us aware of an important geno-
type-phenotype correlation, because similar duplications in FHR5 
and FHR2 have been previously associated with other familial cases 
of C3G. To understand the significance of this peculiar genotype-
phenotype association, we performed a series of biochemical and 
structural analyses with the native and mutant FHR1 proteins that 
unraveled an unexpected structural organization of FHR1, FHR2, 
and FHR5 in human plasma. We showed that FHR1 assembled 
into homo- and hetero-oligomers with FHR2 and FHR5, but did 
not interact with other related proteins, like FHR3, FHR4A/B, FH, 
or FHL1, which lack the 2 conserved N-terminal SCRs. We also 
showed that the mutant FHR1 with the duplicated N-terminus 
generated abnormally large multimers, which appeared as a bun-
dle of fibers as visualized with EM (Figure 6). Together, these data 
suggest that the duplicated N-terminal region of FHR1 includes 
an oligomerization domain and point to the 2 N-terminal SCRs 
conserved in FHR1, FHR2, and FHR5 as the most likely candidate 
domain for this activity. This conclusion is also supported by recent 
structural data demonstrating that the first 2 N-terminal domains 
of these proteins form dimers (13). The location of the oligomeriza-
tion domain at the N-terminus revealed that the FHRs are bifunc-
tional molecules and explains why the FHRs in these complexes 
retain their capacity to interact with C3b and carbohydrates, activi-
ties located in the C-terminal region of FHRs (1, 16, 17).
The structural organization of the FHRs in plasma was com-
plex, but remarkably constant among different individuals, as 
illustrated by the elution profiles from heparin columns (Fig-
ure 3). These experiments also showed that FHR1, the most 
abundant FHR in plasma, played a central role in this structural 
organization. We identified 4 different types of complexes that 
incorporated FHR1 and, using native gels, provided evidence of 
the existence of homo- and heterodimers, as well as higher-order 
oligomeric structures (interpreted here as tetramers), resulting 
from the different combinations of FHR1-FHR1, FHR1-FHR2, 
and FHR1-FHR5 dimers. The FHR composition of the different 
oligomers influenced their elution position from the heparin col-
umn, indicative of different carbohydrate binding characteristics 
for each of these FHR complexes.
These findings have very important functional implications. By 
assembling into homo- and hetero-oligomeric complexes, FHR1, 
FHR2, and FHR5 likely increase their avidity for specific surfaces, 
which supports the concept that these FHRs influence comple-
ment activation and regulation by efficiently competing with 
FH for binding to those surfaces. This is particularly relevant in 
light of the finding that FHRs, but not FH, bound iC3b and C3dg 
(Figure 7B), giving these oligomeric FHR structures a consider-
able advantage for competing with FH on surfaces where iC3b and 
C3dg are present as a consequence of complement activation. In 
this respect, it is important to indicate that the FHR1 oligomers 
did not show cofactor activity for the FI-mediated inactivation of 
iC3b, nor did they inhibit the proteolysis of iC3b by CR1 and FI 
(Supplemental Figure 12). In addition, the generation of a combi-
natorial repertoire of different FHRs may improve surface recogni-
tion, fine-tuning the competition with FH.
Notably, we here describe 2 situations in which this precise FHR 
structural organization is disrupted, with very different outcomes. 
The first is the case of individuals homozygous for the ΔCFHR3-CFHR1 
allele, who lack these FHR1-containing complexes; the second 
is the case of the mutant FHR1 protein. Interestingly, while the 
former confers protection to a number of chronic diseases char-
acterized by complement dysregulation, the anomalous FHR1 
oligomerization caused by the duplication of the oligomerization 
domain had pathogenic consequences, as illustrated by the find-
ing that it was associated with C3G.
The pathogenic consequences of the multimerization of mutant 
FHR1 are likely related to increased avidity for the FHR1 ligands, 
which enhances competition with FH and impairs complement 
regulation on surfaces. We showed that this was the case for the 
Figure 8
Mutant FHR1 shows enhanced competition with FH in a FH-depen-
dent hemolytic assay. Inset shows the preliminary experiment to 
determine the amount of FH to give 30% lysis in the guinea pig 
hemolytic assay. Main plot shows the competition assay between 
native FHR1 (open circles) or mutant FHR1 (filled circles) and FH 
amount. Percent hemolysis was determined as mean ± SD of 3 
independent experiments. The EC50 values — 18.97 nM for native 
FHR1 and 10.97 nM for mutant FHR1 — were significantly different 
(P = 0,001, 2-tailed t test).
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respect, it is perhaps not coincidental that the episodes of disease 
exacerbation in our patients and in other C3G patients carrying 
similar mutant FHRs frequently occur concurrent with infection 
and fever episodes.
Our data, and previous genetic association data indicating that 
deletion of the CFHR1 and CFHR3 genes (ΔCFHR3-CFHR1) is a lower 
risk for factor for AMD (9) and IgA nephropathy (10), suggest that 
the relative amounts of FH and FHR1 may influence disease by 
modulating complement regulation on certain surfaces. In the 
family studied herein, the mother, but not her affected son, carried 
the ΔCFHR3-CFHR1 allele and therefore lacked native FHR1. Whether 
this differential expression of native FHR1 relates to the small 
variations in their disease phenotypes, including the small differ-
ences in the location of the dense deposits observed in the kidney 
biopsies of the mother and son, requires further investigation.
In summary, our identification and functional characteriza-
tion of a mutant FHR1 protein associated with C3G provided 
insights into the biological role of FHRs and has improved our 
understanding of the ways in which mutant FHRs cause pathol-
ogy. Previous studies have shown that the control of complement 
activation is impaired in C3G patients and that dysregulation of 
the complement system may result either from loss of activity 
of the complement regulatory protein FH (21) or from gain-of-
function mutations in C3 that confer to the AP convertase resis-
tance to FH inactivation (22). Those studies also indicated that 
complement dysregulation in prototypical DDD occurs primarily 
in the fluid phase and results in the complete consumption of C3. 
Consistent with the heterogeneity among C3G patients, we show 
here that complement dysregulation on surfaces may also occur 
in other forms of C3G and describe a novel pathogenic mecha-
nism involving an abnormal multimeric FHR1 protein that likely 
causes surface dysregulation. The finding that some C3G patients 
have surface and not fluid-phase complement dysregulation has 
important therapeutic implications. We speculate that it could 
interaction with surface-bound C3b (Figure 7) and provided evi-
dence using a hemolytic assay that the mutant FHR1 competed 
more efficiently than did native FHR1 to reduce the protection 
against complement-mediated lysis conferred by FH (Figure 8). 
Thus, excessive competition between the mutant FHR1 and FH 
represents a novel way to cause complement dysregulation and is 
likely the pathogenic mechanism in our C3G pedigree (Figure 9).
The way that mutant FHR1 causes complement dysregulation 
resembles the effects of C-terminal FH mutations that are asso-
ciated with aHUS. In both cases, the consequence is decreased 
interaction between FH and the surface where complement 
activation needs to be regulated. Why, then, does the excessive 
competition of FH by the mutant FHR1 not result in aHUS? We 
believe that although the FH mutations associated with aHUS 
likely impair binding of FH to most self-surfaces, FHR1 com-
petes the binding of FH to only a subset of those surfaces, and 
this subset does not include the endothelial cell surface. Evidence 
in support of this proposal includes a sheep hemolytic assay 
in which the binding of FH cannot be competed by FHR1 and 
inability of the hybrid FH::FHR1 protein associated with aHUS 
(in which the C-terminus of FH has been replaced by the C-ter-
minus of FHR1) to protect cell surfaces from complement lysis 
(18–20). It is presently unclear on which surfaces FH would be 
primarily competed by the mutant FHR1 protein. As presented 
here, FHR1, FHR2, and FHR5 are deregulators of complement 
activation that, by competing FH, enhance AP activation on 
certain surfaces. One possibility that deserves further investiga-
tion is that the FHRs originated through evolution to prevent 
binding of FH to certain pathogens and that their microbial 
ligands or cross-reacting physiological substances deposited in 
the GBM are the sites of competition between FHR1 and FH. 
Our proposal assumes that there must be low-level C3 activation 
along the GBM (spontaneous, following a trigger, or both) that 
is accelerated in the presence of these mutant proteins. In this 
Figure 9
Proposed model for a novel pathogenic mechanism in C3G. FH is an elongated glycoprotein of 155 kDa composed of 20 SCRs (small 
circles). FH presents C3b binding sites at each end of the molecule. The N-terminal C3b binding site mediates the accelerated decay of 
the AP C3 convertase (C3bBb) and the cofactor activity for the FI-dependent proteolytic inactivation of C3b. The C-terminal region binds 
both C3b and polyanions normally present in the cell surfaces (e.g., sialic acid, heparan sulfates, and glycosaminoglycans). This region is 
essential for the complement regulatory activity of FH on surfaces and to discriminate between self and pathogens, which normally lack 
these polyanions on their surfaces. Extensive experimental data generated during the last 10 years has provided conclusive evidence that 
mutations disrupting the functional activity of the C-terminal region, like those associated with aHUS, decrease the avidity of FH for cell 
surfaces and impair complement regulation (34–36). The data reported here suggest similarities between the established model for the 
aHUS-associated FH mutations and the FHR1 mutant described here. We therefore propose that multimerization of the FHRs as a con-
sequence of duplication of the oligomerization domain in mutant FHR1, FHR2, or FHR5 proteins increases binding to surface-bound C3b, 
iC3b, C3dg, and carbohydrates, resulting in enhanced competition with FH that decreases its complement regulatory capacity and causes 
different degrees of cell surface complement dysregulation.
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MLPA analysis and high-density CGH arrays. Copy number variations and 
genomic rearrangements in the CFH-CFHR1-CFHR5 region were assessed by 
MLPA analysis and custom-designed high-density 8 × 15k oligonucleotide 
CGH arrays spanning the RCA gene cluster region in human chromosome 
1q32 (median resolution, 110 bp; AMADID 040193; Agilent Technologies). 
MLPA analysis was done with genomic DNA with the P236 A1 ARMD mix 1 
(MRC-Holland). For the CGH 8 × 15k microarrays, samples were hybridized 
with sex-matched normal human DNA (Promega Corp.) according to the 
manufacturer’s protocols (31). Microarray data were extracted and visualized 
using Feature Extraction Software (version 10.7) and Genomic Workbench 
Standard Edition (version 7.0; both Agilent Corp). Copy number–altered 
regions were detected using ADM-2 (set as 5) statistic provided by DNA Ana-
lytics, with a minimum number of 5 consecutive probes. Genomic build hg19 
was used for the experiment. All work involved in the hybridization of the 
CGH 8 × 15k microarrays and data extraction was outsourced to Nimgenet-
ics. Microarray data have been deposited in GEO (accession no. GPL16749).
Proteins and Abs. C3b was prepared as previously described from human 
EDTA plasma (32). sDAF was a gift from S. Lea (Oxford University, Oxford, 
United Kingdom). C4bpαΔCT was prepared as previously described (33). 
FH from human plasma was purified by immunoaffinity chromatography. 
Briefly, filtered plasma was loaded into an immunoaffinity column coupled 
to an in-house anti-human FH mouse mAb (mAb214). Bound protein was 
eluted at low pH, and fractions containing the protein were pooled and load-
ed into a Superose-6 column equilibrated with 10 mM HEPES (pH 7.6) and 
100 mM NaCl. MBC125 is a mouse IgG2a mAb raised against a recombinant 
protein containing the first 3 SCRs of FHR1. This Ab recognizes an epitope 
present in FHR1, FHR2, and FHR5 and thus allows for simultaneous quan-
titative detection of the 3 proteins in Western blot analyses. Other Abs were 
in-house mouse mAb MBI-18 against FHR2 (gift from B.P. Morgan, Cardiff 
University School of Medicine, Cardiff, United Kingdom); in-house rabbit 
polyclonal Ab against FHR3 and FHR4 and rabbit polyclonal Ab against 
FHR4 (gifts from P.F. Zipfel and M. Jozsi, Hans Knöll Institute for Natural 
Products Research, Jena, Germany); and OX24, a mouse mAb to FH origi-
nally made by R. Sim (University of Oxford, Oxford, United Kingdom).
BN-PAGE. Samples were analyzed by BN-PAGE. Briefly, the different 
FHRs purified from the heparin columns were dialyzed overnight against 
20 mM HEPES, pH 7.0, and 150 mM NaCl. Samples were mixed with load-
ing buffer (50 mM BisTris, pH 7.2; 50 mM NaCl; 10% [v/v] glycerol; 0.001% 
[v/v] Ponceau S; 0.25% [w/v] Coomassie G-250) and loaded on precast BN-
PAGE gels (Novex BisTris; Invitrogen). Electrophoresis was performed at 
4°C according to the manufacturer’s protocol, and proteins were identi-
fied by silver staining and Western blot. The composition of each band 
detected by BN-PAGE was analyzed by 12% SDS-PAGE followed by West-
ern blot using the MBC125 mAb. Silver staining and Western blots were 
carried out according to standard protocols.
Biosensor analysis/binding affinity assays using SPR. All analyses were carried 
out on a Biacore T100 (GE Healthcare). A nidus of C3b (150 RU) was amine-
coupled to a CM5 (carboxymethylated dextran) sensor chip as instructed by 
the manufacturer (NHS/EDC coupling kit; GE Healthcare). Further C3b 
was deposited via the internal C3 thioester group by forming convertase 
on amine-coupled C3b by flowing 50 μg/ml FB and 1 μg/ml factor D (FD) 
using the same buffer supplemented with 1 mM MgCl2, followed by C3 
as substrate for the convertase (34). 1,240 RU nascent C3b was covalently 
bound to the chip surface. Coupling in this manner results in “clustered” 
C3b on the surface as would be present on a target. To generate iC3b, the 
C3b surface was treated with successive cycles of FH (10 μg/ml) and FI (10 
μg/ml) until convertase could no longer be formed. To generate C3dg, the 
iC3b surface was treated with successive cycles of soluble CR1 (50 μg/ml; gift 
from T Cell Sciences) and FI (10 μg/ml) until no further loss of mass (C3c) 
was evident. To assess binding to C3b, iC3b, or C3dg, samples were injected 
explain why treatment of C3G patients with eculizumab, a human-
ized mAb blocking C5 activation, led to an improvement in renal 
parameters in only approximately half of patients (23–27). The 
pathophysiological heterogeneity of C3G means that the appro-
priate complement-inhibiting strategy will be determined by the 
underlying mechanism of complement dysregulation.
Methods
Patients. GN29 is a 12-year-old boy who, coincident with an episode of fever 
associated with an upper respiratory infection and purulent conjuncti-
vitis by Haemophilus influenzae, presented with macroscopic hematuria at 
15 months of age. 1 month earlier, he had a similar episode that resolved 
spontaneously in 3 days. At that time, moderate fever was also present, as 
well as the macroscopic hematuria and subnephrotic-range proteinuria. 
Blood pressure and renal function were normal. Plasma C3 levels were 
slightly below the normal range. A third episode, similar to the previous 
ones, occurred at age 20 months, precipitating a nephrology review. Despite 
preservation of renal function and normotension, he had persistent micro-
hematuria of variable intensity that becomes macroscopic during intercur-
rent fever. Proteinuria remained in the subnephrotic range with no periph-
eral edema. However, in 2009, he developed edema and nephrotic-range 
proteinuria that was steroid responsive, coincident with a drop in plasma 
C3 levels (Figure 2B). Current medication is angiotensin converting enzyme 
inhibitor (ACEI) therapy, and proteinuria is now in the subnephrotic range. 
Notably, his C3 levels in plasma have always been below the normal range. 
A renal biopsy performed in 2008 revealed glomerular hypertrophy with 
diffuse capillary and mesangial thickening and hypercellularity (Figure 
1A). The GBM was thick due to the linear accumulation of PAS-positive 
material that was also found locally in the mesangium (Figure 1, B and C). 
Immunofluorescence studies revealed very intense granular C3 staining 
along thickened capillary loops (Figure 1D) and within the mesangium, 
where focal IgM staining was also present (Figure 1E). Staining for IgG 
was negative (Figure 1F). Transmission EM demonstrated the presence of 
osmiophilic deposits in the GBM and mesangium (Figure 1G).
GN29M, mother of GN29, had microhematuria, trace proteinuria, arte-
rial hypertension, and decreased plasma C3 levels in a routine screening in 
1999, prior to the in vitro fecundation during her first and only twin preg-
nancy. She delivered by Caesarean section because of preeclampsia. Since 
2002, her hypertension has been controlled with ACEI treatment and diet. 
Her renal function is preserved (0.79 mg/dl creatinine, corresponding to a 
creatinine clearance rate of 140 ml/min). She maintains a persistent vari-
able proteinuria (trace to 50 mg/dl), moderate microhematuria (>50 eryth-
rocytes/field), and chronic hypocomplementemia, with levels of plasma 
C3 persistently below the normal range. A renal biopsy performed in 2009 
showed a C3G with intense C3 deposits similar to those observed in her 
son, negative IgG and IgM staining, and the presence of subendothelial and 
subepithelial GBM and mesangium osmiophilic deposits (Figure 1, H–O).
GN29GF, maternal grandfather of GN29, developed chronic renal insuf-
ficiency at 51 years of age. Renal biopsy diagnosis was membranoprolif-
erative glomerulonephritis type II (now DDD). 6 years later, he presented 
with acute myocardial infarction and multivessel coronary artery disease. 
In 2001, he reached end-stage renal disease. He received a renal transplant, 
but died in 2007 from acute myocardial infarction.
Mutation screening and genotyping. Genomic DNA was obtained from 
peripheral blood mononuclear cells using Puregene Blood Core kit B (QIA-
GEN) according to manufacturer’s instructions. Each exon of the CFH, 
MCP, CFI, C3, and CFB genes was amplified from genomic DNA using spe-
cific primers derived from the 5′ and 3′ intronic sequences, as described pre-
viously (2, 22, 28–30). Automatic sequencing was performed in an ABI 3730 
sequencer using a dye terminator cycle sequencing kit (Applied Biosystems).
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using the “High Performance” command, in HBS/P (10 mM HEPES, pH 
7.4; 150 mM NaCl; 0.01% surfactant-P20) flowed at 20 μl/min and analyzed 
at 25°C. All data were double-referenced (data from control cell and blank 
injection subtracted). The chip surface was regenerated between injections 
using 10 mM sodium acetate, pH 4.0, and 1M NaCl. Data were evaluated 
using Biaevaluation software (version 4.1; GE Healthcare).
FH-dependent hemolytic assay. The capacity of FHR1 and mutant FHR1 to 
compete the activity of FH to control AP on cellular surfaces was assessed 
with a hemolytic assay using guinea pig erythrocytes. In brief, guinea pig 
erythrocytes (TCS Biosciences) in AP buffer (0.5% packed cell volume) —
consisting of veronal buffer saline (2.5 mM barbital; 1.5 mM sodium bar-
bital; 144 mM NaCl, pH 7.4) with 5 mM MgCl2, 8 mM EGTA, and 0.1% 
gelatin — were incubated with sufficient amounts of 10% serum in AP buf-
fer and increasing amounts of FH for 1 hour at 37°C. After centrifugation, 
supernatants were read at 414 nm. Titration of FH before each experiment 
determined conditions for the competition assay. The minimal concentra-
tion of FH giving 30% lysis was mixed with different amounts of FHR1 
proteins to measure their capacity to compete with FH (starting concen-
tration, 150 nM). Serum without added FH was taken as 100% lysis, and 
erythrocytes diluted in AP buffer were used as blank for spontaneous lysis.
EM analyses. Mutant FHR1 preparations were subjected to a final puri-
fication step using size-exclusion Superdex 200 chromatography (GE 
Healthcare) in 20 mM Tris-HCl, pH 7.5, and 350 mM NaCl before the 
preparation of EM grids. A selected fraction was adsorbed onto glow dis-
charged carbon-coated grids and negatively stained with 2% (m/v) ura-
nyl formate. Grids were visualized in a JEOL 1230 transmission electron 
microscope operated at 100 kV, and micrographs were recorded on a 4k × 
4k TVIPS CMOS detector at a nominal magnification of ×50,000.
Statistics. Statistical analysis of the FH-dependent hemolytic assay data 
in Figure 8 was done by 2-tailed t test (independent samples). The anal-
ysis was performed using SPSS software (version 21; SPSS). Results are 
expressed as a mean of 3 independent experiments. A P value of 0.05 or less 
was considered significant.
Study approval. The studies described herein received IRB approval 
(Comision de Bioetica, Consejo Superior de Investigaciones Científicas). 
Patients and their relatives gave their informed consent.
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